LFG
TRVI icon

Larson Financial Group’s Trevi Therapeutics TRVI Stock Holding History

Larson Financial Group’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.4K Buy
1,150
+103
+10% +$1.5K ﹤0.01% 1968
2026
Q1 		$12.5K Buy
1,047
+1,038
+11,533% +$11.6K ﹤0.01% 2110
2025
Q4 		$113 Buy
9
+6
+200% +$69 ﹤0.01% 3331
2025
Q3 		$27 Buy
+3
New +$22 ﹤0.01% 3384

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Larson Financial Group's TRVI Position: Q2 2026 in Review

Larson Financial Group increased its Trevi Therapeutics (TRVI) stake by 9.8% in Q2 2026, buying an estimated $1.5K and bringing the position to 1,150 shares worth $21.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1968.

Larson Financial Group first reported a position in TRVI in Q3 2025 and has held it in 4 quarters since. 218 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • Larson Financial Group held 1,150 shares of Trevi Therapeutics worth $21.4K as of Q2 2026.
  • Larson Financial Group bought 103 Trevi Therapeutics shares in Q2 2026, an estimated $1.5K.
  • Trevi Therapeutics made up ﹤0.01% of Larson Financial Group's portfolio in Q2 2026, its #1968 holding.
  • Larson Financial Group first reported a position in Trevi Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 218 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Larson Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.